Clinical Trials Logo

Filter by:
  • Withdrawn  
  • Page [1]
NCT ID: NCT05083117 Withdrawn - Clinical trials for COVID-19 Acute Respiratory Distress Syndrome

Safety and Efficacy of Inhaled XW001 For Hospitalized COVID-19 Patients Requiring Oxygen Therapy

Start date: October 30, 2021
Phase: Phase 2
Study type: Interventional

This is a multiregional, randomized, double-blind, placebo-controlled Phase 2 study in patients with confirmed symptomatic COVID-19, designed to evaluate the safety, tolerability, efficacy, and PK of XW001 (IL-29 analog) inhalation solution. The purpose of this study is to evaluate whether treatment with XW001 reduces the likelihood of worsening disease in patients with severe COVID-19. Hospitalized patients on oxygen therapy by mask or nasal prongs (WHO-OSCI score 4) will be enrolled.

NCT ID: NCT03048136 Withdrawn - Clinical trials for Non-Small Cell Lung Cancer

A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer

CheckMate 955
Start date: March 9, 2018
Phase: Phase 3
Study type: Interventional

A Study to Evaluate Safety in Participants with Chemotherapy-naïve Stage IV or Recurrent Non-small Cell Lung Cancer Treated With Nivolumab in Combination with Ipilimumab

NCT ID: NCT02392676 Withdrawn - Clinical trials for Platinum Sensitive Relapsed Ovarian Cancer

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

Start date: July 2016
Phase: Phase 3
Study type: Interventional

Olaparib administered as monotherapy in the maintenance setting improves progression free survival compared to placebo in patients whose tumours carry loss of function (deleterious or suspected deleterious) somatic BRCA mutations or loss of function (deleterious or suspected deleterious) mutation in non-BRCA Homologous Recombination Repair (HRR) -associated genes who have a complete or partial response to platinum-based chemotherapy.

NCT ID: NCT01600963 Withdrawn - Clinical trials for Multi-drug Resistant Tuberculosis

A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis

Start date: March 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to provide safety and efficacy data for TMC207 and to demonstrate that TMC207 added to a background regimen (BR) is superior to treatment with the BR plus placebo.

NCT ID: NCT01033474 Withdrawn - Infertility Clinical Trials

Results Following the Vitrification of Human Oocytes Using 2 Methodologies

Start date: December 2009
Phase: N/A
Study type: Observational

The investigators are going to compare embryo developmental rates of human eggs following freezing in two different freezing methods. The investigators are going to compare the pregnancy rates following transfer to patients as well. Null Hypothesis: The type of vitrification methodology used will not have an impact on the following: - Survival rates - Embryonic developmental rates - Pregnancy and implantation rates.

NCT ID: NCT00133458 Withdrawn - Clinical trials for Subarachnoid Cysticercosis

RCT ALB for SA Cysticercosis

Start date: n/a
Phase: Phase 3
Study type: Interventional

This study will enroll 120 individuals diagnosed with subarachnoid cysticercosis, a disease caused by the invasion of the basal part of your brain by a parasite named Taenia solium. Subarachnoid cysticercosis is usually treated with albendazole for one month to kill the parasite. This study will determine if two months of albendazole (ABZ) therapy is better than one-month. The study will last 3 years.